Literature DB >> 489967

Immunotherapy of a murine ovarian carcinoma with Corynebacterium parvum and specific heteroantiserum. I. Activation of peritoneal cells to mediate antibody-dependent cytotoxicity.

R C Bast, R C Knapp, A K Mitchell, J G Thurston, R W Tucker, S F Schlossman.   

Abstract

Immunotherapy with a combination of Corynebacterium parvum and specific heteroantiserum is significantly more effective than treatment with either single agent in prolonging the survival of mice that have recevied an i.p. injection of syngeneic murine ovarian carcinoma (MOT) cells. Invitro, a combination of C. parvum-activated peritoneal cells and specific heteroantiserum has proven significantly more effective than either single component in destroying 51Cr-labeled MOT cells in the absence of complement. Activation of peritoneal cells to produce lysis of tumor in the presence specific antiserum peaked 3 to 7 days after a single injection of C. parvum and declined to baseline over 3 to 4 weeks. With repeated i.p. injections of C. parvum at appropriate intervals, activation of peritoneal cells could be prolonged and augmented. Among the routes tested, only i.p. administration of C. parvum was effective, although activation of peritoneal cells for cooperation with heteroantiserum was observed over a broad range of i.p. dosage (0.45 to 4.20 mg). These data suggest that the administration of C. parvum by appropriate doses, routes, and schedules can attract and activate a population of peritoneal effectors that mediate antibody-dependent cytotoxicity more effectively than resident peritoneal cells.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 489967

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Modification of monoclonal antibody carbohydrates by oxidation, conjugation, or deoxymannojirimycin does not interfere with antibody effector functions.

Authors:  M Awwad; P G Strome; S C Gilman; H R Axelrod
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

2.  Menningococcal antigens (MA): a novel immune stimulant in experimental neoplasia.

Authors:  J A Teodorczyk-Injeyan; B G Sparkes; J M Dupuy; V V Micusan; R E Falk
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

3.  Reflection on the discovery of carcinoembryonic antigen, prostate-specific antigen, and cancer antigens CA125 and CA19-9.

Authors:  Eleftherios P Diamandis; Robert C Bast; Phil Gold; T Ming Chu; John L Magnani
Journal:  Clin Chem       Date:  2012-11-30       Impact factor: 8.327

4.  Recent progress in the treatment of epithelial ovarian malignancy.

Authors:  J S Berek; N F Hacker; L D Lagasse
Journal:  West J Med       Date:  1982-10

5.  Antibody-dependent cellular cytotoxicity-mediated serotherapy against murine neuroblastoma. I. In vitro and in vivo treatment using normal, gamma-irradiated and immune-stimulated rat effector cells.

Authors:  J E Byfield; R Zerubavel; E W Fonkalsrud
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

6.  Reactivity of a monoclonal antibody with human ovarian carcinoma.

Authors:  R C Bast; M Feeney; H Lazarus; L M Nadler; R B Colvin; R C Knapp
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

Review 7.  The Role of Cutibacterium acnes in Sarcoidosis: From Antigen to Treatable Trait?

Authors:  Raisa Kraaijvanger; Marcel Veltkamp
Journal:  Microorganisms       Date:  2022-08-15

8.  Role of activated macrophages in antibody-dependent lysis of tumor cells.

Authors:  C Nathan; L Brukner; G Kaplan; J Unkeless; Z Cohn
Journal:  J Exp Med       Date:  1980-07-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.